Destiny Pharma | Evaluate

With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.

The UK company insists that by the end of the year a partner will have been found for its microbiome project to prevent C difficile infections.

July 02, 2021

October 12, 2017

Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.

March 03, 2016

Latest Reports